Jeffrey Wayne
Internal Medicine · Lincoln, CANPI 1689750325
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,334 of the $13,654 with a category attached, or 68.4%. 11 manufacturers reported payments, led by AstraZeneca at 50.1% of the total. Reporting peaked in 2024 at $6,112 and has fallen 86.7% since, to $814 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $145.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Novo Nordisk AS$2K
- Novartis$2K
- Merck$1K
- Astrazeneca UK Limited$1K
- Pfizer$1K
- plus $262 from 5 others
Across 2,640 payments — averaging $4097.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.6M
- Novartis$1.5M
- Eli Lilly$1.3M
- Novo Nordisk AS$1.1M
- Pfizer$892K
- Applied Therapeutics, Inc.$536K
- plus $2.8M from 27 others
What the payments were for
- Speaking & faculty fees$8406%
- Travel & lodging$9,33468%
- Food & beverage$3,48025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $6,847 |
| Novo Nordisk AS | 4 | $1,591 |
| Novartis | 9 | $1,590 |
| Merck | 13 | $1,136 |
| Astrazeneca UK Limited | 5 | $1,119 |
| Pfizer | 2 | $1,109 |
| Boehringer Ingelheim | 2 | $100 |
| Corcept Therapeutics | 1 | $50 |
| Lilly USA, LLC | 2 | $41 |
| Novo Nordisk | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
How this compares
$13,654 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrochlorothiazide | 23 | $62 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lincoln
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.